Learning from aprotinin - Mandatory trials of comparative efficacy and safety needed

New England Journal of Medicine

Volumn 358, Issue 8, 2008, Pages 840-842

  Ray, Wayne A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; PLASMIN; TRANEXAMIC ACID;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; HEART INFARCTION; HEART SURGERY; HUMAN; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; RISK; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 39549121469     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0800268     Document Type: Editorial

References (16)

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-11.
2. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
3. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
4. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83.
5. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008;358:784-93.
6. Center for Drug Evaluation and Research. Early communication about an ongoing safety review: aprotinin injection (marketed as Trasylol). Beltsville, MD: Food and Drug Administration, 2007.
7. Chen RH, Frazier OH, Cooley DA. Antifibrinolytic therapy in cardiac surgery. Tex Heart Inst J 1995;22:211-5.
8. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. N Engl J Med 2006;354:194-201.
9. Hiatt WR. Observational studies of drug safety - aprotinin and the absence of transparency. N Engl J Med 2006;355:2171-3.
10. Ferguson TB Jr. Aprotinin - are there lessons learned? JAMA 2007;297:527-9.
11. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886.
12. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. St. Louis: Mosby-Year Book, 1996.
13. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
14. White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244-50.
15. Wood AJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-23. [Erratum, N Engl J Med 2006;355:2712.]
16. Psaty BM, Korn D. Congress responds to the IOM drug safety report - in full. JAMA 2007;298:2185-7.